PSMA Theranostics: The New Age of Prostate Cancer Imaging and Treatment

Session 3: PSMA Theranostics: The New Age of Prostate Cancer Imaging and Treatment
Thursday, October 28, 2021 | 9:40 AM – 12:00 PM PST

Moderator:
Michael Hofman, MBBS, Peter MacCallum Cancer Centre; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC), Australia

LuPSMA: The Newest Treatment Class for Advanced Prostate Cancer
Michael Hofman, MBBS, Peter MacCallum Cancer Centre; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC), Australia

Results from the PRINCE Trial: Testing the Combination of LuPSMA with Pembrolizumab in mCRPC
Shahneen Sandhu, MBBS, Peter MacCallum Cancer Centre, Australia

Targeting Micro-Metastatic Disease with Auger or Alpha Emitters
Ana Kiess, MD, PhD, Johns Hopkins University

The Four Sisters of Terbium: PET & SPECT Imaging and Targeted Alpha- & Beta-Therapy
Cristina Müller, PhD, PD, Paul Scherrer Institute, Switzerland

aPROMISE: An Artificial Intelligence Platform to Assist in Standardizing the Detection, Localization and Quantification of Prostate Cancer in PYLARIFY PSMA Scans
Aseem Anand, PhD, Imaging-Oncology Biomarker, EXINI Diagnostics AB. Sweden (a wholly owned subsidiary of Lantheus Holdings)

Targeting Fibroblast Activation Protein-alpha (FAP) in Prostate Cancer: Is FAP the Next Theranostic Target after PSMA in Prostate Cancer?
Andy Simmons, PhD, Clovis Oncology

Insights & Future Predictions from 25 Years of PSMA Research
Neil Bander, MD, Weill Cornell Medical College

82 cents of every dollar donated goes to our prostate cancer research mission

Join the fight against prostate cancer today. Donate